Luminal Breast Carcinoma a disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LMN015 MIFTS: 36	Luminal Breast Carcinoma a Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Luminal Breast Carcinoma a

MalaCards integrated aliases for Luminal Breast Carcinoma a:

Name: Luminal Breast Carcinoma a ¹²

Breast Tumor Luminal ¹² ¹⁷

Luminal a Breast Carcinoma ¹²

Luminal Breast Carcinoma ¹⁵

Luminal Breast Cancer ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0060548

NCIt ⁴⁹ C53554

EFO ¹⁷ EFO_0000306

UMLS ⁷¹ C3642345

Sources

Summaries for Luminal Breast Carcinoma a

Disease Ontology : ¹² A breast carcinoma that is characterized by high expression of genes characteristic of luminal epithelial cells, including estrogen receptor (ER), estrogen regulated protein LIV-1, and the transcription factors hepatocyte nuclear factor 3, HNF3A, XBP1, and GATA 3.

MalaCards based summary : Luminal Breast Carcinoma a, also known as breast tumor luminal, is related to adenocarcinoma and estrogen-receptor positive breast cancer. An important gene associated with Luminal Breast Carcinoma a is KDM4C (Lysine Demethylase 4C), and among its related pathways/superpathways are Deubiquitination and Pathways in cancer. The drugs Vitamin D and Calcium, Dietary have been mentioned in the context of this disorder. Affiliated tissues include breast, and related phenotypes are cellular and endocrine/exocrine gland

Sources

Related Diseases for Luminal Breast Carcinoma a

Diseases in the Luminal Breast Carcinoma a family:

Luminal Breast Carcinoma B

Diseases related to Luminal Breast Carcinoma a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 368)

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	30.7	TP53 PIK3CA ERBB2 EGFR CDH1
2	estrogen-receptor positive breast cancer	30.3	TP53 PIK3CA PGR GATA3 FOXA1 ESR1
3	breast adenocarcinoma	30.2	TP53 PIK3CA PGR LCOR H2AC18 ESR1
4	breast ductal carcinoma	29.9	TP53 PGR KRT5 ESR1 ERBB2 EGFR
5	leukemia, acute myeloid	29.5	TP53 PIK3CA MIR21 LCOR KDM4C H2AC18
6	ductal carcinoma in situ	29.5	TP53 PIK3CA PGR KRT5 ESR1 ERBB2
7	in situ carcinoma	29.4	TP53 PIK3CA PGR LCOR KRT5 H2AC18
8	breast cancer	29.0	TP53 PIK3CA PGR MIR21 KRT5 H2AC18
9	luminal breast carcinoma b	12.6
10	bartholin's gland adenoid cystic carcinoma	10.7	PGR ESR1
11	chronic tympanitis	10.7	PGR ESR1
12	granulomatous endometritis	10.7	PGR ESR1
13	uterine corpus adenosarcoma	10.7	PGR ESR1
14	vaginal glandular tumor	10.7	PGR ESR1
15	glassy cell carcinoma of the cervix	10.7	PGR ESR1 ERBB2
16	oncocytic breast carcinoma	10.7	PGR ESR1 ERBB2
17	lung leiomyoma	10.7	PGR ESR1
18	vulvar syringoma	10.7	PGR ESR1
19	inverted transitional papilloma	10.7	KRT5 GATA3
20	trigonitis	10.7	PGR ESR1
21	cervical serous adenocarcinoma	10.7	PGR GATA3
22	lipid-rich breast carcinoma	10.6	PGR KRT5 ERBB2
23	hereditary gastric cancer	10.6	CDH1 CD44
24	breast mucinous carcinoma	10.6	PGR KRT5 ERBB2
25	cervical clear cell adenocarcinoma	10.6	PGR ESR1
26	bartholin's gland adenoma	10.6	TP53 PGR ESR1
27	bartholin's gland benign neoplasm	10.6	TP53 PGR ESR1
28	vestibular gland benign neoplasm	10.6	TP53 PGR ESR1
29	scirrhous adenocarcinoma	10.6	PGR ERBB2 CDH1
30	synchronous bilateral breast carcinoma	10.6	PGR BRCA1
31	endometrial squamous cell carcinoma	10.6	TP53 PGR
32	mucoepidermoid esophageal carcinoma	10.6	TP53 KRT5
33	rare head and neck tumor	10.6	TP53 PIK3CA
34	ovarian seromucinous carcinoma	10.6	TP53 PGR ESR1
35	breast squamous cell carcinoma	10.6	KRT5 ERBB2
36	apocrine adenosis of breast	10.6	TP53 PGR ERBB2
37	benign breast adenomyoepithelioma	10.6	KRT5 ESR1 EGFR
38	recurrent respiratory papillomatosis	10.6	ERBB2 EGFR
39	adult type testicular granulosa cell tumor	10.6	PGR ESR1
40	breast adenoid cystic carcinoma	10.6	TP53 PGR ERBB2
41	bizarre leiomyoma	10.6	TP53 PGR ESR1
42	subserous uterine fibroid	10.6	PGR CYP19A1
43	microinvasive cervical squamous cell carcinoma	10.6	KRT5 GATA3
44	breast cystic hypersecretory carcinoma	10.6	KRT5 ERBB2 CDH1
45	linitis plastica	10.6	PGR ERBB2 CDH1
46	mammographic density	10.6	PGR ESR1 CYP19A1
47	gastric papillary adenocarcinoma	10.6	TP53 ERBB2
48	wolffian duct adenocarcinoma	10.6	TP53 GATA3 ESR1
49	biphasic synovial sarcoma	10.6	PGR ESR1 CDH1
50	familiar ovarian carcinoma	10.6	PIK3CA BRCA1

Graphical network of the top 20 diseases related to Luminal Breast Carcinoma a:

Sources

Symptoms & Phenotypes for Luminal Breast Carcinoma a

MGI Mouse Phenotypes related to Luminal Breast Carcinoma a:

⁴⁵ (show all 19)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.35	BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
2	endocrine/exocrine gland	MP:0005379	10.35	BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
3	growth/size/body region	MP:0005378	10.34	BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
4	cardiovascular system	MP:0005385	10.32	BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
5	homeostasis/metabolism	MP:0005376	10.32	BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
6	integument	MP:0010771	10.32	BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
7	digestive/alimentary	MP:0005381	10.3	BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
8	mortality/aging	MP:0010768	10.28	BRCA1 CD44 CDH1 EGFR ERBB2 ESR1
9	immune system	MP:0005387	10.27	BRCA1 CD44 CDH1 CYP19A1 EGFR ESR1
10	embryo	MP:0005380	10.2	BRCA1 CDH1 EGFR ERBB2 ESR1 GATA3
11	adipose tissue	MP:0005375	10.13	BRCA1 CYP19A1 EGFR ESR1 GATA3 PIK3CA
12	neoplasm	MP:0002006	10.11	BRCA1 CD44 CDH1 EGFR ERBB2 ESR1
13	muscle	MP:0005369	10.1	BRCA1 CD44 CYP19A1 EGFR ERBB2 ESR1
14	limbs/digits/tail	MP:0005371	10.06	BRCA1 CD44 EGFR ERBB2 ESR1 KRT5
15	normal	MP:0002873	9.96	BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
16	no phenotypic analysis	MP:0003012	9.92	CDH1 EGFR ESR1 GATA3 KDM4C PGR
17	reproductive system	MP:0005389	9.7	BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
18	pigmentation	MP:0001186	9.63	BRCA1 CD44 CYP19A1 EGFR GATA3 TP53
19	skeleton	MP:0005390	9.32	BRCA1 CD44 CYP19A1 EGFR ERBB2 ESR1

Sources

Drugs & Therapeutics for Luminal Breast Carcinoma a

Drugs for Luminal Breast Carcinoma a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4

1406-16-2

Calcium, Dietary

Phase 4

Calciferol

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

Palbociclib

Approved, Investigational

Phase 3

571190-30-2

5005498 11431660 5330286

Fulvestrant

Approved, Investigational

Phase 3

129453-61-8

104741 17756771

Goserelin

Approved

Phase 3

65807-02-5

5311128 47725

Protein Kinase Inhibitors

Phase 3

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Letrozole

Approved, Investigational

Phase 2

112809-51-5

3902

Anastrozole

Approved, Investigational

Phase 2

120511-73-1

2187

Exemestane

Approved, Investigational

Phase 2

107868-30-4

60198

Tamoxifen

Approved

Phase 2

10540-29-1

2733526

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Epirubicin

Approved

Phase 2

56420-45-2

41867

Tubulin Modulators

Phase 2

Antimitotic Agents

Phase 2

Albumin-Bound Paclitaxel

Phase 2

Hormone Antagonists

Phase 2

Estrogen Antagonists

Phase 2

Estrogen Receptor Antagonists

Phase 2

Liposomal doxorubicin

Phase 2

31703

Aromatase Inhibitors

Phase 2

Estrogens

Phase 2

Hormones

Phase 2

Estrogen Receptor Modulators

Phase 2

taxane

Phase 2

Immunosuppressive Agents

Phase 2

Alkylating Agents

Phase 2

Anti-Bacterial Agents

Phase 2

Immunologic Factors

Phase 2

Antirheumatic Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Antineoplastic Agents, Hormonal

Interventional clinical trials:

(show all 12)

#	Name	Status	NCT ID	Phase	Drugs
1	Hormone Therapy Initiation Immediately After Histological Diagnosis of Breast Cancer, Can it Make Any Difference?	Unknown status	NCT03111615	Phase 4	Aromatase Inhibitors
2	Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant®	Recruiting	NCT03447132	Phase 3	Fulvestrant 500mg;Palbociclib 125mg;Goserelin 3.6 MG;Placebos
3	Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer	Unknown status	NCT01565499	Phase 2	Nab-paclitaxel
4	A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy.	Unknown status	NCT02506556	Phase 2	BYl719
5	Phase Ib Followed by Phase II Study of Pre-operative Treatment With Lenvatinib Combined With Letrozole in Post-menopausal Women With Newly Diagnosed Hormone Receptor Positive Breast Cancer With Measurable Primary Breast Tumor	Unknown status	NCT02562118	Phase 1, Phase 2	Lenvatinib + Letrozole
6	Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.	Recruiting	NCT03283384	Phase 2	Letrozole;Chemotherapy;Ribociclib plus letrozole
7	Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer	Recruiting	NCT04023292	Phase 2	Endocrine therapy;Endocrine therapy
8	Group Sequential Response Adaptive Randomized Clinical Trial of Concomitant Chemotherapy Plus Endocrine Therapy Versus Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Plus Endocrine Therapy for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer.	Recruiting	NCT03227328	Phase 2	concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy;chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
9	A Phase II Window-of-opportunity Study of Single Agent Lenvatinib in Estrogen Receptor Positive Early Stage Breast Cancer	Recruiting	NCT03168074	Phase 2	lenvatinib
10	Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women	Active, not recruiting	NCT02400567	Phase 2	Fluorouracile;Epirubicin;Cyclophosphamide;Letrozole;Palbociclib
11	Immediate Breast Reconstruction With Free Greater Omentum for Luminal Breast Cancer Patients	Recruiting	NCT03370250
12	Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Impact of Drug Adherence/Persistence on Clinical Outcome in Various Breast Cancer Subtypes	Active, not recruiting	NCT03761420

Search NIH Clinical Center for Luminal Breast Carcinoma a

Sources

Genetic Tests for Luminal Breast Carcinoma a

Sources

Anatomical Context for Luminal Breast Carcinoma a

MalaCards organs/tissues related to Luminal Breast Carcinoma a:

⁴⁰

Breast

Sources

Publications for Luminal Breast Carcinoma a

Articles related to Luminal Breast Carcinoma a:

#	Title	Authors	PMID	Year
1	Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer. ⁶¹	Qin T...Wang S	28739755	2017

Sources

Genes for Luminal Breast Carcinoma a

Genes related to Luminal Breast Carcinoma a (0 elite genes):

(show all 40)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	KDM4C	Lysine Demethylase 4C	Protein Coding	8.56	DISEASES inferred ¹⁵ ¹⁵
2	MIR21	MicroRNA 21	RNA Gene	8.32	DISEASES inferred ¹⁵ ¹⁵
3	LCOR	Ligand Dependent Nuclear Receptor Corepressor	Protein Coding	8.29	DISEASES inferred ¹⁵ ¹⁵
4	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	8.28	DISEASES inferred ¹⁵
5	ESR1	Estrogen Receptor 1	Protein Coding	8.17	DISEASES inferred ¹⁵
6	MIR19B1	MicroRNA 19b-1	RNA Gene	7.97	DISEASES inferred ¹⁵ ¹⁵
7	PGR	Progesterone Receptor	Protein Coding	7.76	DISEASES inferred ¹⁵
8	H2AC18	H2A Clustered Histone 18	Protein Coding	7.68	DISEASES inferred ¹⁵ ¹⁵
9	FOXA1	Forkhead Box A1	Protein Coding	7.42	DISEASES inferred ¹⁵
10	GATA3	GATA Binding Protein 3	Protein Coding	7.23	DISEASES inferred ¹⁵
11	MIR513A1	MicroRNA 513a-1	RNA Gene	7.22	DISEASES inferred ¹⁵ ¹⁵
12	KRT5	Keratin 5	Protein Coding	7.01	DISEASES inferred ¹⁵
13	MIR548D1	MicroRNA 548d-1	RNA Gene	6.92	DISEASES inferred ¹⁵ ¹⁵
14	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.86	DISEASES inferred ¹⁵
15	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	6.8	DISEASES inferred ¹⁵
16	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	6.76	DISEASES inferred ¹⁵
17	TP53	Tumor Protein P53	Protein Coding	6.67	DISEASES inferred ¹⁵
18	CDH1	Cadherin 1	Protein Coding	6.66	DISEASES inferred ¹⁵
19	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	6.65	DISEASES inferred ¹⁵
20	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	6.64	DISEASES inferred ¹⁵
21	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.61	DISEASES inferred ¹⁵
22	CD24	CD24 Molecule	Protein Coding	6.58	DISEASES inferred ¹⁵
23	ELF5	E74 Like ETS Transcription Factor 5	Protein Coding	6.48	DISEASES inferred ¹⁵
24	SNAI2	Snail Family Transcriptional Repressor 2	Protein Coding	6.4	DISEASES inferred ¹⁵
25	ZNF703	Zinc Finger Protein 703	Protein Coding	6.38	DISEASES inferred ¹⁵
26	EGF	Epidermal Growth Factor	Protein Coding	6.36	DISEASES inferred ¹⁵
27	SNAI1	Snail Family Transcriptional Repressor 1	Protein Coding	6.35	DISEASES inferred ¹⁵
28	KRT14	Keratin 14	Protein Coding	6.35	DISEASES inferred ¹⁵
29	KRT8	Keratin 8	Protein Coding	6.34	DISEASES inferred ¹⁵
30	ITGA6	Integrin Subunit Alpha 6	Protein Coding	6.31	DISEASES inferred ¹⁵
31	DSCAM-AS1	DSCAM Antisense RNA 1	RNA Gene	6.21	DISEASES inferred ¹⁵
32	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	6.2	DISEASES inferred ¹⁵
33	ZEB1	Zinc Finger E-Box Binding Homeobox 1	Protein Coding	6.18	DISEASES inferred ¹⁵
34	CCND1	Cyclin D1	Protein Coding	6.16	DISEASES inferred ¹⁵
35	ERBB3	Erb-B2 Receptor Tyrosine Kinase 3	Protein Coding	6.14	DISEASES inferred ¹⁵
36	CDK4	Cyclin Dependent Kinase 4	Protein Coding	6.13	DISEASES inferred ¹⁵
37	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.13	DISEASES inferred ¹⁵
38	TFAP2C	Transcription Factor AP-2 Gamma	Protein Coding	6.12	DISEASES inferred ¹⁵
39	EPCAM	Epithelial Cell Adhesion Molecule	Protein Coding	6.1	DISEASES inferred ¹⁵
40	KRT18	Keratin 18	Protein Coding	6.06	DISEASES inferred ¹⁵

Sources

Variations for Luminal Breast Carcinoma a

Sources

Expression for Luminal Breast Carcinoma a

Search GEO for disease gene expression data for Luminal Breast Carcinoma a.

Sources

Pathways for Luminal Breast Carcinoma a

Pathways related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	Deubiquitination ⁶⁵ Show member pathways Ub-specific processing proteases ⁶⁵	12.75	TP53 H2AC18 GATA3 ESR1 BRCA1
2	Pathways in cancer ³⁶	12.73	TP53 PIK3CA ESR1 ERBB2 EGFR CDH1
3	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁵ MET activates STAT3 ⁶⁵ Neurotrophin signaling pathway ³⁶ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.61	TP53 PIK3CA ESR1 ERBB2 CDH1
4	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	12.51	TP53 PIK3CA ESR1 ERBB2 EGFR CDH1
5	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.42	TP53 PIK3CA PGR ESR1 ERBB2 EGFR
6	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁴	12.31	PIK3CA ESR1 CD44 BRCA1
7	Shigellosis ³⁶	12.3	TP53 PIK3CA EGFR CD44
8	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.22	PIK3CA ESR1 ERBB2 EGFR
9	Translation Non-genomic (rapid) action of Androgen Receptor ²² Show member pathways Basal cell carcinoma ³⁶ Transcription Androgen Receptor nuclear signaling ²²	12.21	TP53 PIK3CA ERBB2 EGFR
10	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶³ ErbB receptor signaling network ¹	12.21	PIK3CA ERBB2 EGFR CDH1
11	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	11.93	TP53 PIK3CA ERBB2 EGFR
12	Integrated Breast Cancer Pathway ¹	11.92	TP53 ESR1 EGFR CYP19A1 CDH1 BRCA1
13	Signaling by ERBB4 ⁶⁵ Show member pathways Downregulation of ERBB4 signaling ⁶⁵ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁵	11.84	PIK3CA PGR ESR1 ERBB2 EGFR
14	Proteoglycans in cancer ³⁶	11.81	TP53 PIK3CA MIR21 ESR1 ERBB2 EGFR
15	MicroRNAs in cancer ³⁶	11.72	TP53 PIK3CA MIR21 MIR19B1 ERBB2 EGFR
16	Glucocorticoid receptor regulatory network ¹	11.71	TP53 KRT5 GATA3
17	Platinum drug resistance ³⁶	11.66	TP53 PIK3CA ERBB2 BRCA1
18	Bladder cancer ³⁶ ¹	11.64	TP53 ERBB2 EGFR CDH1
19	Adherens junction ³⁶	11.63	ERBB2 EGFR CDH1
20	Central carbon metabolism in cancer ³⁶	11.6	TP53 PIK3CA ERBB2 EGFR
21	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.55	TP53 PIK3CA ERBB2 BRCA1
22	Hepatitis C and Hepatocellular Carcinoma ¹	11.46	TP53 CD44 BRCA1
23	FOXA1 transcription factor network ¹ Show member pathways FOXA transcription factor networks ¹	11.41	FOXA1 ESR1 BRCA1
24	a6b1 and a6b4 Integrin signaling ¹	11.11	PIK3CA ERBB2 EGFR CDH1
25	E-cadherin signaling in keratinocytes ¹	10.97	PIK3CA EGFR CDH1
26	Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics ⁶⁰	10.15	ESR1 CYP19A1

Sources

GO Terms for Luminal Breast Carcinoma a

Cellular components related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nuclear chromatin	GO:0000790	9.17	TP53 PGR KDM4C H2AC18 GATA3 FOXA1

Biological processes related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

(show all 19)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	10.09	TP53 PGR GATA3 FOXA1 ESR1 EGFR
2	positive regulation of transcription, DNA-templated	GO:0045893	9.95	TP53 GATA3 ESR1 EGFR CDH1 BRCA1
3	positive regulation of gene expression	GO:0010628	9.8	TP53 MIR21 KDM4C GATA3 ERBB2 BRCA1
4	positive regulation of kinase activity	GO:0033674	9.73	ERBB2 EGFR CD44
5	chromatin remodeling	GO:0006338	9.71	KDM4C GATA3 FOXA1 ESR1
6	response to estrogen	GO:0043627	9.7	GATA3 ESR1 BRCA1
7	response to estradiol	GO:0032355	9.67	FOXA1 ESR1 EGFR CYP19A1
8	phosphatidylinositol 3-kinase signaling	GO:0014065	9.63	PIK3CA GATA3 ERBB2
9	negative regulation of gene expression	GO:0010629	9.63	TP53 PGR MIR21 MIR19B1 GATA3 ESR1
10	ERBB2 signaling pathway	GO:0038128	9.61	PIK3CA ERBB2 EGFR
11	regulation of transcription by RNA polymerase II	GO:0006357	9.61	TP53 LCOR KDM4C GATA3 FOXA1 ESR1
12	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.58	TP53 EGFR
13	positive regulation of RNA polymerase II transcriptional preinitiation complex assembly	GO:0045899	9.58	TP53 ESR1
14	negative regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903799	9.57	TP53 ESR1
15	positive regulation of histone H3-K9 acetylation	GO:2000617	9.54	GATA3 BRCA1
16	negative regulation of ERBB signaling pathway	GO:1901185	9.51	ERBB2 EGFR
17	cellular response to indole-3-methanol	GO:0071681	9.49	CDH1 BRCA1
18	uterus development	GO:0060065	9.43	GATA3 ESR1 CYP19A1
19	positive regulation of protein kinase B signaling	GO:0051897	9.1	PIK3CA MIR21 GATA3 ESR1 ERBB2 EGFR

Molecular functions related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA-binding transcription factor activity, RNA polymerase II-specific	GO:0000981	9.91	TP53 PGR LCOR GATA3 FOXA1 ESR1
2	zinc ion binding	GO:0008270	9.85	TP53 PGR KDM4C GATA3 ESR1 BRCA1
3	chromatin binding	GO:0003682	9.72	TP53 KDM4C FOXA1 ESR1 EGFR
4	transcription regulatory region DNA binding	GO:0044212	9.71	TP53 GATA3 FOXA1 BRCA1
5	DNA-binding transcription activator activity, RNA polymerase II-specific	GO:0001228	9.65	TP53 PGR GATA3 FOXA1 ESR1
6	ATPase binding	GO:0051117	9.63	PGR ESR1 EGFR
7	identical protein binding	GO:0042802	9.56	TP53 PGR GATA3 ESR1 ERBB2 EGFR
8	nitric-oxide synthase regulator activity	GO:0030235	9.16	ESR1 EGFR
9	enzyme binding	GO:0019899	9.1	TP53 PGR KDM4C ESR1 EGFR BRCA1

Sources

Sources for Luminal Breast Carcinoma a

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia